Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Wils

Showing results (71-80 of 115) with videos related to

Pageof 12
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1993
Phase II study of sequential high-dose methotrexate (MTX) and 5-fluorouracil (F) alternated with epirubicin (E) and cisplatin (P) [FEMTX-P] in advanced gastric cancerE J Roelofs, D J Wagener, T Conroy, et al.
Oral Diseases|June 29, 2022
Oral leukoplakia classification and staging system with incorporation of differentiated dysplasiaElisabeth R Brouns, Ilkay Evren, Leon J Wils, et al.
Oral Diseases|October 3, 2021
Associations between clinical and histopathological characteristics in oral leukoplakiaIlkay Evren, Elisabeth R Brouns, Jos B Poell, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 1997
Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983-1987). European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative GroupD Nitti, J Wils, T Sahmoud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1996
Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer StudyG Blijham, T Wagener, J Wils, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1993
Adjuvant chemohormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive breast cancer patientsP S Hupperets, J Wils, L Volovics, et al.
British Journal of Cancer|July 4, 1998
Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cyclesR de Wit, H van den Berg, J Burghouts, et al.
European Journal of Cancer (Oxford, England : 1990)|December 9, 1997
Gastrointestinal Tract Cancer Liaison Office: an attempt to organise clinical research in EuropeH Bleiberg, B Gerard, J Wils, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2022
Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant TransformationLeon J Wils, Jos B Poell, Arjen Brink, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2004
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trialsG Folprecht, D Cunningham, P Ross, et al.
Pageof 12

Showing results (71-80 of 115) with videos related to

Sort By:
Pageof 12
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1993
Phase II study of sequential high-dose methotrexate (MTX) and 5-fluorouracil (F) alternated with epirubicin (E) and cisplatin (P) [FEMTX-P] in advanced gastric cancerE J Roelofs, D J Wagener, T Conroy, et al.
Oral Diseases|June 29, 2022
Oral leukoplakia classification and staging system with incorporation of differentiated dysplasiaElisabeth R Brouns, Ilkay Evren, Leon J Wils, et al.
Oral Diseases|October 3, 2021
Associations between clinical and histopathological characteristics in oral leukoplakiaIlkay Evren, Elisabeth R Brouns, Jos B Poell, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 1997
Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983-1987). European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative GroupD Nitti, J Wils, T Sahmoud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1996
Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer StudyG Blijham, T Wagener, J Wils, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1993
Adjuvant chemohormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive breast cancer patientsP S Hupperets, J Wils, L Volovics, et al.
British Journal of Cancer|July 4, 1998
Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cyclesR de Wit, H van den Berg, J Burghouts, et al.
European Journal of Cancer (Oxford, England : 1990)|December 9, 1997
Gastrointestinal Tract Cancer Liaison Office: an attempt to organise clinical research in EuropeH Bleiberg, B Gerard, J Wils, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2022
Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant TransformationLeon J Wils, Jos B Poell, Arjen Brink, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2004
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trialsG Folprecht, D Cunningham, P Ross, et al.
Pageof 12